Sharda Cropchem Limited – Investor Presentation Summary

Key Operational Highlights

  • Global operations span 80+ countries with a network of 525+ distributors and 500+ sales professionals.
  • The company holds a portfolio of 3,016 registrations, which are core intellectual property assets.
  • Capital expenditure for Q1 FY27 was ₹263 crores.
  • Key drivers include an asset-light, registration-led business model and a flexible supply network primarily sourcing from China.

Segment-wise Performance

The company operates two business segments supported by a shared platform of global sourcing, registrations, and distribution:

  • Agrochemicals: Core business of crop protection solutions including Herbicides, Fungicides, Insecticides, and Biocides.
  • Agrochemicals Non-Agrochemical: Leverages existing capabilities to serve industrial applications including products for Rubber and Conveyor Belts, Dyes and Dye Intermediates, and Industrial Chemicals.

Financial Highlights

  • Revenue from Operations: ₹1,073.8 Cr (9% YoY growth from ₹984.8 Cr in Q1 FY26)
  • Gross Profit: ₹394.0 Cr (13% YoY growth from ₹349.2 Cr)
  • Gross Margin: 36.7% (120 bps improvement YoY from 35.5%)
  • EBITDA: ₹178.4 Cr (25% YoY growth from ₹142.2 Cr)
  • EBITDA Margin: 16.6% (220 bps improvement YoY from 14.4%)
  • PAT: ₹88.0 Cr (-38% YoY from ₹142.8 Cr)
  • PAT Margin: 8.2% (down from 14.5% in Q1 FY26)
  • EPS: ₹9.76 (down from ₹15.83 in Q1 FY26)

Drivers of financial performance: The significantly lower forex gain of ₹7.5 Cr in Q1 FY27 versus ₹73.1 Cr in Q1 FY26 resulted in a corresponding impact on EBIT, PBT, and PAT. PBT prior to forex gains was ₹110.9 Cr, showing 16% YoY growth from ₹96.0 Cr.

Geographical Revenue Split

Not specified in the presentation.

Balance Sheet Snapshot

As of March 31, 2026:

  • Total Equity: ₹3,137.0 Cr
  • Total Non-Current Liabilities: ₹257.1 Cr
  • Total Current Liabilities: ₹2,386.2 Cr
  • Total Assets: ₹5,780.3 Cr
  • Non-Current Assets: ₹1,342.2 Cr (including Other Intangible Assets of ₹986.2 Cr and Intangible assets under development of ₹247.2 Cr)
  • Current Assets: ₹4,438.1 Cr (including Inventories of ₹1,119.6 Cr and Trade Receivables of ₹2,389.3 Cr)
  • Cash & Cash equivalents: ₹219.8 Cr

Financial Health Insights: The company maintains a strong balance sheet with no borrowings in the non-current liabilities as of March 2026.

Capex & Cash Flow Health

  • Capital Expenditure (Q1 FY27): ₹263 Crs
  • Free Cash Flow: Not specified
  • Operating Cash Flow: Not specified
  • Net Debt Movement: Not specified

Investment Rationale: Focus on building regulatory assets through dossier development and maintaining an asset-light operational model.

Strategic & R&D Initiatives

Investments in Innovation: Continuous investment in developing dossiers and securing registrations for off-patent molecules. The company identifies opportunities by monitoring patent landscapes, crop trends, and regulatory developments.

Strategic Rationale: The IP-led growth model creates long-term market access, strong competitive differentiation, and high entry barriers. The company is strengthening its platform through forward integration (factory-to-farmer approach), expanding distribution presence, and focusing on operational efficiencies.

Industry Trends & Business Environment

Not specified in the presentation.

Management Commentary & Growth Outlook

Strategic Outlook: The company is "Building the Next Phase" centered on regulatory expertise, market access, portfolio depth, and customer proximity while maintaining financial discipline and operational excellence.

Key Priorities:

  • Forward Integration — Building the Sales Force
  • Expand and Strengthen Distribution Presence
  • Continual Investment in Registrations
  • Focus on Operational Efficiencies
  • Deepen Portfolio & Maintain Financial Discipline

FY Guidance: Not specified.

Market Share Targets: Not specified.

Risks and Opportunities: The presentation notes forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause actual results to differ materially, including: (a) ability to successfully implement strategy, (b) growth and expansion plans, (c) changes in regulatory norms, (d) technological changes, (e) investment income, (f) cash flow projections, and (g) other risks.